AstraZeneca_NNP Annual_JJ Report_NNP and_CC Group_NNP Financial_NNP Record_NNP US_NNP GAAP_NNP 126_CD Form_NN 20-F_JJ Information_NN 2003_CD Group_NNP Financial_NNP Record_NNP US_NNP GAAP_NNP Group_NNP Financial_NNP Record_NNP US_NNP GAAP_NNP The_DT selected_VBN financial_JJ data_NNS set_VBN out_RP below_IN for_IN each_DT of_IN the_DT years_NNS in_IN the_DT five_CD year_NN period_NN ended_VBD 31_CD December_NNP 2003_CD ,_, has_VBZ been_VBN extracted_VBN or_CC derived_VBN from_IN audited_JJ Financial_NNP Statements_NNP ._.
The_DT selected_VBN financial_JJ data_NNS should_MD be_VB read_VBN in_IN conjunction_NN with_IN ,_, and_CC are_VBP qualified_VBN in_IN their_PRP$ entirety_NN by_IN reference_NN to_TO ,_, the_DT Financial_NNP Statements_NNP of_IN AstraZeneca_NNP and_CC the_DT notes_NNS thereto_RB ,_, which_WDT are_VBP included_VBN elsewhere_RB in_IN this_DT document_NN ._.
Consolidated_NNP income_NN statement_NN data_NN For_IN the_DT years_NNS ended_VBN 31_CD December_NNP 1999 2000 2001 2002_CD 2003_CD Net_JJ income_NN loss_NN from_IN operations_NNS $_$ m_CD 3,539_CD 865_CD 1,397_CD 2,307_CD 2,268_CD Net_JJ income_NN loss_NN from_IN operations_NNS per_IN Ordinary_NNP Share_NNP $_$ 2.26_CD $_$ 0.49_CD $_$ 0.79_CD $_$ 1.33_CD $_$ 1.33_CD Diluted_VBN income_NN loss_NN from_IN operations_NNS per_IN Ordinary_NNP Share_NNP $_$ 2.26_CD $_$ 0.49_CD $_$ 0.79_CD $_$ 1.33_CD $_$ 1.33_CD Net_JJ income_NN loss_NN from_IN operations_NNS had_VBD SFAS_NNP No._NN ._.
142_CD been_VBN adopted_VBN 2,833_CD 1,716_CD 2,125_CD Net_NN and_CC diluted_JJ income_NN loss_NN per_IN Ordinary_NNP Share_NN from_IN operations_NNS had_VBD SFAS_NNP No._NN ._.
142_CD been_VBN adopted_VBN $_$ 1.81_CD $_$ 0.97_CD $_$ 1.21_CD Ratio_NN of_IN earnings_NNS to_TO fixed_JJ charges_NNS For_IN the_DT Group_NNP with_IN estimated_VBN material_NN adjustments_NNS to_TO accord_VB with_IN US_NNP GAAP_NNP 19.3_CD 15.5_CD 25.0_CD 36.7_CD 78.9_CD Consolidated_NNP balance_NN sheet_NN data_NNS At_IN 31_CD December_NNP 1999 2000 2001 2002_CD 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Total_JJ assets_NNS 46,640_CD 41,500_CD 38,081_CD 42,578_CD 45,378_CD Shareholders_NNS equity_NN 33,735_CD 29,707_CD 27,402_CD 30,183_CD 33,654_CD Merger_NNP accounting_NN For_IN the_DT purpose_NN of_IN US_NNP GAAP_NNP ,_, the_DT merger_NN has_VBZ been_VBN regarded_VBN as_IN a_DT purchase_NN accounting_NN acquisition_NN of_IN Astra_NNP by_IN Zeneca_NNP ._.
Ratio_NN of_IN earnings_NNS to_TO fixed_JJ charges_NNS UK_NNP and_CC US_NNP GAAP_NNP For_IN the_DT purpose_NN of_IN computing_VBG these_DT ratios_NNS ,_, earnings_NNS consist_VBP of_IN the_DT income_NN from_IN continuing_VBG ordinary_JJ activities_NNS before_IN taxation_NN of_IN Group_NNP companies_NNS and_CC income_NN received_VBN from_IN companies_NNS owned_VBN 50_CD %_NN or_CC less_JJR ,_, plus_CC fixed_VBN charges_NNS excluding_VBG capitalized_JJ interest_NN ._.
Fixed_VBN charges_NNS consist_VBP of_IN interest_NN including_VBG capitalized_JJ interest_NN on_IN all_DT indebtedness_NN ,_, amortisation_NN of_IN debt_NN discount_NN and_CC expense_NN and_CC that_IN portion_NN of_IN rental_JJ expense_NN representative_NN of_IN the_DT interest_NN factor_NN ._.
The_DT comparative_JJ figures_NNS have_VBP been_VBN restated_VBN from_IN those_DT previously_RB disclosed_VBN to_TO reflect_VB the_DT reclassification_NN of_IN the_DT operations_NNS of_IN Specialties_NNS and_CC Agrochemicals_NNPS as_IN discontinued_VBN ._.
